FDA Okays Generics for ISTURISA Tablets
Published Date: 9/30/2026
Notice
Summary
The FDA has decided that ISTURISA (osilodrostat) 10 mg tablets were not taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions of ISTURISA, as long as they meet all the rules. Patients and pharmacies could see more affordable options soon, with no safety worries involved.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Generic makers may seek approval
The FDA determined that ISTURISA (osilodrostat) 10 mg tablets were not withdrawn for reasons of safety or effectiveness, so abbreviated new drug applications (ANDAs) that refer to ISTURISA (NDA 212801) may be approved if they meet all other legal and regulatory requirements. This determination follows a citizen petition dated April 24, 2026, and references the original approval of ISTURISA on March 6, 2020.
Product listed as discontinued for non-safety reasons
FDA will continue to list ISTURISA (osilodrostat) 10 mg in the Orange Book 'Discontinued Drug Product List,' which denotes products discontinued from marketing for reasons other than safety or effectiveness. The Agency reviewed records and postmarketing data and found no information indicating withdrawal for safety or effectiveness.
Possible labeling updates for ANDA applicants
The FDA said that if it determines ISTURISA's labeling should be revised to meet current standards, the Agency will advise ANDA applicants to submit such updated labeling when seeking approval for a generic version. ANDA approval remains contingent on meeting all other legal and regulatory requirements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-19967, National Register of Historic Places; Notification of Pending Nominations and Related Actions
The National Park Service is asking for your thoughts on historic places nominated before September 12, 2026, to be added to the National Register of Historic Places. If you care about preserving history, now’s your chance to comment by October 15, 2026. This affects communities, historians, and anyone who loves protecting special sites, with no cost to participate—just your voice!
Next: 2026-19969, Agency Information Collection Activities; Interjurisdictional Invasive Species Rapid Response Team Program
The Fish and Wildlife Service is asking for your thoughts on a new plan to collect info for a team that quickly fights invasive species crossing state lines. If you’re involved in wildlife, environmental work, or just care about nature, this affects you! You’ve got until November 30, 2026, to share your ideas—no cost changes yet, just making sure the info collection is clear and helpful.